Immunoliposomes provide a complementary, and in many instances advantageous, drug
delivery strategy to antibody-drug conjugates. Their high carrying capacity of 20,000 …

Dendritic cells (DCs)-based immunotherapy has shown immense promise in systemic lupus
erythematosus (SLE) treatment. However, existing carrier strategies such as polymers …

Autoimmune diseases are caused by breaking the central and/or peripheral tolerance
against self, leading to uncontrolled immune response to autoantigens. The incidences of …

Autoimmune diseases are chronic, destructive diseases that can cause functional disability
and multiple organ failure. Despite significant advances in the range of therapeutic agents …

Nanoparticles, especially liposomes, have gained prominence in the field of drug delivery
for the treatment of human diseases, particularly cancer; they provide several advantages …

Disease‐modifying drugs and biologics used to treat autoimmune diseases, although
promising, are non‐curative. As the field moves toward development of new approaches to …

Autoimmune diseases are burdensome conditions that affect a significant fraction of the
global population. The hallmark of autoimmune disease is a host's immune system being …

Dendritic cells (DCs) are paramount in initiating and guiding immunity towards a state of
activation or tolerance. This bidirectional capacity of DCs sets them at the center stage for …

There is no curative treatment for chronic auto‐inflammatory diseases including rheumatoid
arthritis, and current treatments can induce off‐target side effects due to systemic immune …

Multiple sclerosis is a disease caused by autoantigen-responsive immune cells that disrupt
the myelin in the central nervous system (CNS). Although immunosuppressive drugs are …